Aranda Pharma is focused on developing innovative therapies targeting androgen receptor-related conditions, specifically androgenetic alopecia (AGA) and acne. Their lead candidate, ADA-308, is a highly potent small molecule designed to act as a topical antiandrogen, effectively inhibiting androgen receptor (AR) signaling. This novel drug has shown promising results in preclinical studies, demonstrating superior efficacy compared to existing treatments while maintaining a clean safety profile. Unlike traditional systemic antiandrogens, ADA-308 is applied locally, minimizing systemic side effects and making it suitable for both men and women suffering from AGA and acne.

The mechanism of action for ADA-308 involves binding to the androgen receptor, preventing androgens from triggering AR-mediated signaling that leads to hair follicle miniaturization in AGA and excessive sebum production in acne. This targeted approach not only reduces the adverse effects commonly associated with systemic treatments but also enhances the therapeutic potential for patients. With excellent solubility and stability in topical formulations, ADA-308 is positioned as a best-in-class, non-steroidal alternative for managing these androgen-related disorders, paving the way for future combination therapies with other topical agents.

Finland

Aranda Pharma is a preclinical stage pharmaceutical company. We are developing novel non-steroidal small molecule inhibitors of the androgen receptor, that are advanced as locally acting antiandrogens for the topical treatment of acne and androgenetic alopecia.

Aranda Pharma

Company Details